Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30540488 | 0.92 | GRM2 (0.37) | KLKB1KDM4ETERTTP53RXFP1 | |
| SCHEMBL30540617 | 0.92 | TERT (0.35) | KLKB1KDM4ELMNAALDH1A1L3MBTL1 | |
| SCHEMBL30540453 | 0.84 | KLKB1 (0.39) | KLKB1KDM4ELMNAALDH1A1L3MBTL1 | |
| SCHEMBL30540512 | 0.84 | HRH3 (0.39) | KDM4ELMNAALDH1A1HRH3TP53 | |
| SCHEMBL30540580 | 0.83 | KLKB1 (0.37) | KLKB1KDM4ELMNAALDH1A1L3MBTL1 | |
| SCHEMBL30577653 | 0.81 | KLKB1 (0.36) | KLKB1KDM4ELMNAALDH1A1L3MBTL1 | |
| SCHEMBL25353088 | 0.81 | TERT (0.42) | KDM4ELMNAALDH1A1L3MBTL1HRH3 | |
| SCHEMBL30577552 | 0.81 | TERT (0.42) | KDM4ELMNAALDH1A1L3MBTL1HRH3 | |
| SCHEMBL31578220 | 0.77 | CBLB (0.51) | TERT | |
| SCHEMBL31115338 | 0.77 | KDM4E (0.36) | KLKB1KDM4ELMNAALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163047-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE, LTD. (KY) | 2025-05-22 | — | — | US | disclosed |
| EP-4476219-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BeiGene, Ltd. (KY) | 2024-12-18 | — | — | EP | disclosed |
| CN-118696043-A | Heterocyclic compounds, compositions thereof and methods of treatment therewith | 百济神州有限公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2023151636-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023151641-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163047-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | NFATC1, GZMB, IFNG | KLKB1 3730/4885KDM4E 996/4885LMNA 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.